Royal London Asset Management
WST icon

Royal London Asset Management’s West Pharmaceutical WST Stock Holding History

Royal London Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1M Sell
83,818
-15,732
-16% -$4.81M 0.06% 263
2026
Q1 		$25M Buy
99,550
+7,136
+8% +$1.78M 0.05% 283
2025
Q4 		$25.4M Buy
92,414
+40,712
+79% +$11.1M 0.05% 277
2025
Q3 		$13.6M Buy
51,702
+16,598
+47% +$4.03M 0.03% 393
2025
Q2 		$7.68M Sell
35,104
-966
-3% -$207K 0.02% 480
2025
Q1 		$8.08M Buy
36,070
+2,642
+8% +$728K 0.02% 474
2024
Q4 		$10.9M Buy
33,428
+1,368
+4% +$431K 0.03% 408
2024
Q3 		$9.62M Buy
32,060
+454
+1% +$139K 0.02% 426
2024
Q2 		$10.4M Sell
31,606
-273
-0.9% -$96.5K 0.03% 393
2024
Q1 		$12.6M Sell
31,879
-916
-3% -$339K 0.03% 358
2023
Q4 		$11.5M Buy
32,795
+1,515
+5% +$536K 0.03% 362
2023
Q3 		$11.7M Buy
31,280
+3,113
+11% +$1.2M 0.04% 337
2023
Q2 		$10.8M Buy
28,167
+3,290
+13% +$1.18M 0.03% 350
2023
Q1 		$8.62M Buy
24,877
+1,443
+6% +$422K 0.03% 354
2022
Q4 		$5.52M Hold
23,434
– – 0.02% 431
2022
Q3 		$5.77M Sell
23,434
-1,132
-5% -$345K 0.03% 400
2022
Q2 		$7.44M Hold
24,566
– – 0.03% 358
2022
Q1 		$10.1M Buy
24,566
+2,292
+10% +$897K 0.04% 331
2021
Q4 		$10.4M Hold
22,274
– – 0.04% 335
2021
Q3 		$9.46M Hold
22,274
– – 0.04% 338
2021
Q2 		$8M Hold
22,274
– – 0.03% 378
2021
Q1 		$6.28M Buy
22,274
+927
+4% +$265K 0.03% 425
2020
Q4 		$6.05M Buy
21,347
+653
+3% +$183K 0.03% 383
2020
Q3 		$5.66M Buy
+20,694
New +$5.48M 0.03% 369

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Royal London Asset Management's WST Position: Q2 2026 in Review

Royal London Asset Management reduced its West Pharmaceutical (WST) stake by 16% in Q2 2026, selling an estimated $4.81M and leaving 83,818 shares worth $30.1M. The position accounts for 0.06% of the portfolio, ranked #263.

Royal London Asset Management first reported a position in WST in Q3 2020 and has held it in 24 quarters since. 832 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Royal London Asset Management held 83,818 shares of West Pharmaceutical worth $30.1M as of Q2 2026.
  • Royal London Asset Management sold 15,732 West Pharmaceutical shares in Q2 2026, an estimated $4.81M.
  • West Pharmaceutical made up 0.06% of Royal London Asset Management's portfolio in Q2 2026, its #263 holding.
  • Royal London Asset Management first reported a position in West Pharmaceutical in Q3 2020 and has held it in 24 quarters since.
  • 832 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.